Probiotics for Diverticulitis: Evidence-Based Strains That Support the Colon
What the peer-reviewed research says about gut bacteria, diverticular disease, and the strains with the strongest clinical evidence
Diverticular disease affects an estimated 35% of adults in Western countries by age 50, and that figure climbs steeply with age—reaching over 65% by age 85.[1] For the millions who experience painful flares, recurrent cramping, and persistent bloating, conventional treatment often centers on antibiotics, dietary modification, and watchful waiting. But a growing body of research points to a piece of the puzzle that conventional protocols largely overlook: the gut microbiome.
Acute diverticulitis is now understood to be, at its core, an inflammatory condition driven in part by microbial imbalance. When beneficial bacteria decline and pro-inflammatory species proliferate within the colon's diverticula—the small pouches that form in the intestinal wall—the conditions for inflammation are set. That understanding has led researchers to ask an obvious question: can restoring microbial balance with targeted probiotics reduce the frequency, severity, and duration of diverticulitis episodes?
This article examines the peer-reviewed clinical evidence on probiotics for diverticulitis, with a focus on strains that have been specifically studied in this context—and that happen to be among the 26 strains found in MicroBiome Restore. We also address what the research does and doesn't yet tell us, because intellectual honesty about the limitations of the current evidence is part of what distinguishes science-backed supplementation from marketing noise.
Key Takeaways
- Dysbiosis is a core driver of diverticulitis. Patients with acute diverticulitis show reduced populations of anti-inflammatory bacteria—including Lactobacillus and Bifidobacterium—and increased pro-inflammatory species compared to healthy controls.[2]
- Lactobacillus reuteri has the strongest single-strain RCT evidence. Two randomized, double-blind, placebo-controlled trials found that L. reuteri ATCC PTA 4659 significantly reduced abdominal pain, CRP, and calprotectin—and shortened hospital stays—in patients with acute uncomplicated diverticulitis.[3][4]
- A three-strain combination including L. acidophilus, B. lactis, and L. salivarius significantly outperformed antibiotics alone for pain reduction and inflammatory biomarker suppression in acute uncomplicated diverticulitis.[5]
- L. paracasei showed a statistically significant prevention effect in a 12-month double-blind RCT—with acute diverticulitis occurring in only 1 of 53 patients in the probiotic group versus 6 of 52 in the placebo group.[6]
- A 2025 systematic review and meta-analysis found probiotic therapy was associated with significant improvement in abdominal pain (SMD 0.63) and reduced risk of recurrence (RR 0.22), with multi-strain, longer-duration regimens showing the most benefit.[7]
- Multi-strain, filler-free formulations matter: synthetic inactive ingredients like microcrystalline cellulose and magnesium stearate can undermine the gut environment probiotics are meant to restore.
What Is Diverticulitis?
Diverticulosis refers to the presence of diverticula—small, bulging pouches that develop in the lining of the colon, typically in the sigmoid region. The formation of these pouches is linked to structural changes in the colonic wall, low dietary fiber intake, altered gut motility, and microbiome disruption, among other factors.[1] Most people with diverticulosis never develop symptoms.
Diverticulitis occurs when one or more of these pouches becomes inflamed or infected. Symptoms typically include left lower abdominal pain (sometimes severe), fever, nausea, and changes in bowel habits. The clinical classification distinguishes between symptomatic uncomplicated diverticular disease (SUDD)—chronic, recurring abdominal discomfort without acute inflammation—and acute uncomplicated diverticulitis (AUD), which involves an active inflammatory episode. Complicated diverticulitis involves abscess formation, perforation, or fistula, and represents a medical emergency requiring surgical evaluation.
Treatment for acute episodes traditionally involves antibiotics, bowel rest, and fluid therapy. However, updated guidelines in several countries have moved toward selective antibiotic use in mild uncomplicated cases—which has opened the door for adjunct strategies like probiotics to be evaluated more rigorously.[2]
Diverticulitis vs. Diverticulosis: What's the Difference?
Diverticulosis is simply the presence of diverticula in the colon wall—a structural condition that affects the majority of older adults and causes no symptoms for most. Diverticulitis is what happens when those pouches become inflamed, often triggered by bacterial overgrowth and dysbiosis within the pouches themselves. Understanding this distinction matters because probiotic research targets both phases: reducing inflammation and symptom burden in active SUDD, and potentially preventing acute flares in people with diverticulosis.
The Gut Microbiome Connection
The link between gut dysbiosis and diverticular disease has become one of the most active research areas in gastroenterology. Fecal microbiome analyses of patients across the spectrum of diverticular disease consistently show a pattern: as disease severity increases, microbial diversity decreases, and specific beneficial genera decline.[2]
In patients developing acute diverticulitis, researchers have documented significant reductions in anti-inflammatory bacterial taxa—specifically Clostridium cluster IV, Lactobacillus, and Bacteroides—alongside a corresponding increase in pro-inflammatory species including Enterobacteriaceae.[2] This creates a mutually reinforcing cycle: dysbiosis promotes mucosal inflammation, and mucosal inflammation further disrupts microbial balance.
The consequences of this imbalance extend beyond the microbiome itself. Beneficial bacteria—particularly Lactobacillus and Bifidobacterium species—produce short-chain fatty acids (SCFAs) like butyrate, which serve as the primary energy source for colonocytes (colon-lining cells) and play a critical role in maintaining intestinal barrier integrity. When these bacteria decline, SCFA production drops, the mucosal barrier weakens, and bacterial translocation from within diverticula into surrounding tissue becomes more likely—contributing to the pericolonic inflammation that characterizes acute diverticulitis. This is the same mechanism driving the connection between gut dysbiosis and intestinal permeability more broadly.
Notably, a 2025 systematic review found that patients with diverticular disease show a reduction in Akkermansia muciniphila—a mucin-degrading bacterium critical for epithelial barrier function—alongside declines in SCFA-producing populations.[7] These findings reinforce the mechanistic rationale for probiotic intervention: restoring the beneficial bacterial populations that protect the colonic mucosa from within.
The Dysbiosis-Inflammation Feedback Loop in Diverticulitis
In healthy individuals, commensal bacteria compete for nutrients, produce antimicrobial substances, and physically occupy adhesion sites on the mucosal wall that might otherwise be colonized by pathogenic species. In diverticular disease, this protective function is compromised. Fecal stasis within diverticula creates a microenvironment that favors bacterial overgrowth, which can activate Toll-like receptors in the diverticular mucosa, triggering an inflammatory cascade in perivisceral tissue. Probiotics interrupt this cycle through multiple mechanisms: competitive exclusion of pathogens, modulation of inflammatory cytokines (particularly TNF-α, IL-6, and CRP), and reinforcement of mucosal barrier function.[2]
How Probiotics Work in Diverticular Disease
Probiotics don't simply repopulate a depleted gut with generic "good bacteria." The mechanisms by which specific strains benefit diverticular disease are increasingly well-characterized, and they map directly onto the pathophysiology of the condition.
Anti-Inflammatory Activity
Several probiotic strains—particularly Lactobacillus species—have demonstrated the ability to suppress inflammatory cytokine production, including TNF-α, IL-6, and C-reactive protein (CRP). This anti-inflammatory action is particularly relevant in gut dysbiosis scenarios where low-grade, chronic mucosal inflammation perpetuates symptoms. Experimental models have documented that Lactobacillus acidophilus and Bifidobacterium lactis significantly reduce these inflammatory markers in colonic tissue challenged with inflammatory stimuli.[8]
Competitive Exclusion of Pathogens
Beneficial bacteria occupy adhesion sites on the colonic mucosa and produce bacteriocins—antimicrobial compounds—that inhibit the growth of pathogenic species. In diverticular pouches, this competitive pressure can help prevent the bacterial overgrowth that initiates inflammatory episodes. This is the same principle that underlies probiotic use after antibiotic courses, where restoring microbial balance after antibiotics is a well-established application.
Mucosal Barrier Reinforcement
Certain Lactobacillus strains upregulate mucin-3 expression and strengthen tight junction proteins in the intestinal epithelium, directly improving the barrier between the gut lumen and surrounding tissue.[8] A compromised gut barrier is central to how bacterial translocation from diverticula escalates into acute diverticulitis.
Motility Normalization
Altered gut motility—often a result of neuronal and muscular dysfunction driven by dysbiosis—contributes to the prolonged fecal transit that allows material to stagnate within diverticula. Research suggests that probiotic-mediated restoration of microbial balance can help normalize colonic motility signals, reducing the conditions that favor diverticular inflammation.[2]
26 Clinically Studied Strains. Zero Fillers.
MicroBiome Restore delivers every strain discussed in this article—plus 19 additional evidence-backed strains—alongside 7 certified organic prebiotic sources in a single daily pullulan capsule. No MCC. No magnesium stearate. No titanium dioxide.
Best Probiotic Strains for Diverticulitis
Not all probiotic strains are equal for diverticular disease. The following strains have the most direct clinical evidence—and all are found in MicroBiome Restore. It's worth noting that the research landscape for probiotics in diverticulitis is still developing; the studies cited here represent the current best evidence, but the field calls for continued larger-scale trials before definitive clinical guidelines can be established.
Lactobacillus reuteri: The Most Studied Strain for Acute Diverticulitis
Among all probiotic strains studied in the context of diverticulitis, Lactobacillus reuteri has the deepest and most direct RCT evidence base. The L. reuteri ATCC PTA 4659 strain has been the subject of two double-blind, randomized, placebo-controlled trials specifically in patients with acute uncomplicated diverticulitis—making it uniquely positioned among available research.
The first trial, published in the International Journal of Colorectal Disease, enrolled 88 patients with confirmed acute uncomplicated diverticulitis. All received standard antibiotic therapy; the intervention group additionally received L. reuteri ATCC PTA 4659 for 10 days. Between days 1 and 3, the probiotic group experienced significantly greater pain reduction (4.5 points vs. 2.36 points on the VAS scale, p<0.0001), and the probiotic group's mean hospital stay was 3.8 days versus 4.8 days in the placebo group.[3]
The second trial, published in the European Journal of Gastroenterology & Hepatology, was designed to test L. reuteri without antibiotics—aligning with updated clinical guidelines that question routine antibiotic use in mild cases. In 119 patients with AUD treated with only bowel rest, fluids, and either L. reuteri or placebo, the probiotic group showed significantly greater reductions in both blood CRP and fecal calprotectin at 72 hours.[4] Patients in the probiotic group also had shorter hospitalizations, a finding with direct economic implications for healthcare systems.
The mechanistic basis for L. reuteri's effectiveness in diverticulitis relates to its potent inhibition of proinflammatory cytokines, including TNF-α, and its demonstrated ability to prevent adhesion of pathogenic bacteria to colonic mucosa. You can read more about the broader research on Lactobacillus reuteri benefits in our dedicated strain guide.
Lactobacillus paracasei: Prevention of Acute Diverticulitis Episodes
Lactobacillus paracasei has an extensive research record in diverticular disease—particularly in preventing the progression from symptomatic uncomplicated diverticular disease to acute diverticulitis. A multicenter, 12-month, double-blind, placebo-controlled study analyzed the preventive effects of L. paracasei CNCM I-1572 (also documented as L. casei DG) administered at 24 billion CFU/day for 10 days per month. Of the 7 acute diverticulitis events recorded across 105 patients during follow-up, 6 occurred in the placebo group and only 1 in the probiotic group (p = 0.036).[6]
Multiple earlier trials using L. casei/L. paracasei variants demonstrated statistically significant maintenance of remission in SUDD patients at 6 and 12 months—particularly when combined with mesalazine, where 100% of patients in the combination group remained symptom-free compared to 76.7% in either monotherapy arm.[9]
A 2012 multicenter randomized trial additionally found that L. paracasei B21060 combined with a high-fiber diet produced significant reductions in both abdominal pain duration and bloating intensity compared to a high-fiber diet alone in SUDD patients—with the proportion of patients with abdominal pain lasting less than 24 hours dropping from 100% at baseline to just 25% after 6 months in the probiotic group.[10]
Lactobacillus acidophilus: Inflammation Reduction and Barrier Support
Research has specifically identified Lactobacillus acidophilus as one of the strains effective in managing acute diverticulitis, particularly in multi-strain combinations.[8] A clinical trial using a three-strain probiotic blend containing L. acidophilus LA 201, Bifidobacterium lactis LA 304, and L. salivarius LA 302 demonstrated that patients receiving this combination alongside antibiotics experienced significantly greater reductions in abdominal pain and inflammatory markers compared to those receiving antibiotics alone.[5]
L. acidophilus is one of the best-characterized probiotic species for intestinal barrier support—a critical factor in diverticulitis, where mucosal integrity directly influences whether bacteria within diverticula can translocate and trigger inflammation. For a deeper look at this strain's mechanisms, see our overview of Lactobacillus acidophilus benefits.
Bifidobacterium lactis: Anti-Inflammatory Support in Acute Diverticulitis
Bifidobacterium lactis was one of three strains in the multi-strain probiotic combination that significantly reduced abdominal pain and CRP levels when used as an adjunct to antibiotic therapy in acute uncomplicated diverticulitis.[5] At the experimental level, B. lactis combined with L. acidophilus was shown to restore colonic antioxidant status, reduce TNF-α, interleukins, and CRP, and downregulate caspase-3 in an acute diverticulitis model.[8]
Bifidobacterium species are also among the groups that show the most consistent decline in patients with symptomatic diverticular disease and acute diverticulitis—making their supplementation a logically targeted intervention to restore protective microbial populations.[2] Understanding Bifidobacterium lactis's broader clinical applications provides further context for its role in GI inflammation.
Lactobacillus salivarius: Multi-Strain Partner for Acute Episodes
Lactobacillus salivarius LA 302 was the third component of the probiotic combination that outperformed antibiotics alone in acute uncomplicated diverticulitis, reducing both inflammatory biomarkers and abdominal pain intensity.[5] In the broader inflammation literature, L. salivarius Ls33 has been specifically identified as among the highest-performing strains for inducing anti-inflammatory IL-10 and suppressing pro-inflammatory IL-12—a dual action that supports mucosal recovery in inflamed tissue.
Lactobacillus plantarum and Lactobacillus rhamnosus: Barrier and Microbiome Diversity
Lactobacillus plantarum has demonstrated intestinal barrier-strengthening effects by modulating tight junction proteins and reducing intestinal permeability in clinical and preclinical models—addressing one of the core vulnerabilities in diverticulitis pathophysiology. When diverticular bacteria cannot translocate through a compromised mucosal barrier, the inflammatory cascade is interrupted at its source. Read more about the clinical evidence for L. plantarum in gut health.
Lactobacillus rhamnosus is among the most extensively studied probiotic strains globally, with established evidence for immune modulation and maintenance of intestinal microbial diversity. While its diverticulitis-specific RCT data is more limited than L. reuteri or L. paracasei, it contributes to multi-strain formulations' broader microbiome-restoration effects. Explore the full research profile of L. rhamnosus benefits in our strain library.
The 2025 meta-analysis reinforced an important point about formulation strategy: multi-strain probiotics administered over longer durations showed the most consistent benefits in diverticular disease, with a pooled risk ratio for recurrence of 0.22 (95% CI: 0.095–0.510) across two RCTs.[7] Single-strain, short-duration supplementation was less reliable—reinforcing why strain diversity and sustained use both matter in this context.
| Strain | Primary Role in Diverticular Disease | Key Evidence |
|---|---|---|
| L. reuteri | Reduces acute pain, CRP, calprotectin; shortens hospital stay | Two double-blind RCTs in AUD[3][4] |
| L. paracasei / L. casei | Prevents acute diverticulitis occurrence; maintains SUDD remission | 12-month double-blind RCT, multiple clinical trials[6][9][10] |
| L. acidophilus | Reduces inflammatory markers; supports mucosal barrier | Multi-strain RCT in AUD; experimental model[5][8] |
| B. lactis | Suppresses TNF-α, IL-6, CRP; antioxidant support | Multi-strain RCT in AUD; experimental model[5][8] |
| L. salivarius | Anti-inflammatory cytokine modulation; pain reduction | Multi-strain RCT in AUD[5] |
| L. plantarum | Intestinal barrier reinforcement; tight junction support | Preclinical and clinical barrier studies |
| L. rhamnosus | Immune modulation; microbiome diversity support | Broad GI clinical literature; multi-strain evidence |
The Role of Prebiotics in Diverticular Disease
Probiotics don't operate in a vacuum—they require fermentable substrate to colonize effectively and produce the SCFAs that protect the colonic mucosa. This is where prebiotics become clinically relevant for diverticular disease, and where the synbiotic approach (combining probiotics with prebiotic fibers) shows particular promise.
Dietary fiber has long been a cornerstone recommendation in diverticular disease management, partly because it promotes healthy colonic transit and prevents the fecal stasis within diverticula that sets the stage for bacterial overgrowth and inflammation. What's increasingly understood is that the mechanism runs through the microbiome: fiber's benefit is largely mediated by its fermentation into SCFAs by beneficial gut bacteria—exactly the bacteria depleted in diverticulitis.[7]
The 2012 randomized trial of L. paracasei B21060 found that the probiotic-plus-high-fiber-diet arm significantly outperformed fiber alone for abdominal pain and bloating outcomes in SUDD—supporting the idea that prebiotic substrate enhances the clinical benefit of probiotic supplementation.[10]
MicroBiome Restore includes 7 certified organic prebiotic sources: Jerusalem artichoke (a concentrated natural source of inulin, a well-studied prebiotic fiber), Acacia senegal (a soluble fiber with prebiotic properties shown to support Bifidobacterium and Lactobacillus populations in sensitive guts), maitake mushroom (a source of beta-glucans that support immune modulation), fig fruit, bladderwrack, Norwegian kelp, and oarweed. Maltodextrin is included specifically as a cryoprotectant for the probiotic strains during lyophilization, ensuring shelf-stable viability without refrigeration. The pullulan capsule itself carries mild prebiotic properties while providing superior oxygen and moisture barrier function compared to standard HPMC capsules.
Why the Synbiotic Approach Matters for Diverticular Disease
Clinical research increasingly supports what mechanistic logic predicts: probiotics perform better when paired with prebiotic substrate. The fibers in MicroBiome Restore's formula—particularly inulin from Jerusalem artichoke and the soluble fiber from Acacia senegal—provide selectively fermentable fuel that helps the probiotic strains colonize and thrive in the colon, rather than simply passing through.
What to Look for in a Probiotic for Diverticulitis
Choosing a probiotic for diverticular disease requires a more discerning lens than picking a general digestive supplement. The clinical evidence points to several formulation factors that influence whether a probiotic is likely to deliver meaningful benefit.
Multi-Strain Diversity
The 2025 meta-analysis found that multi-strain regimens administered over longer durations showed more consistent benefit than single-strain, short-term supplementation.[7] This makes intuitive sense: diverticulitis involves dysbiosis across multiple bacterial taxa, and restoring microbial balance requires replacing a diversity of depleted populations—not just one. Look for formulas that include both Lactobacillus and Bifidobacterium genera, as both have documented roles in diverticular disease pathophysiology and management. For a deeper understanding of this principle, our guide to single vs. multi-strain probiotics walks through the evidence.
Clinically Studied Strain Inclusion
Not every strain in a multi-strain formula has diverticulitis-specific evidence. The strains with the most direct research—L. reuteri, L. paracasei, L. acidophilus, B. lactis, and L. salivarius—should all be present in an evidence-aligned formula. Verify that individual strains are listed (not buried in a "proprietary blend") so you can confirm what you're actually taking.
Filler-Free Formulation
Many commercial probiotics include inactive ingredients that have their own gastrointestinal effects—and not beneficial ones. Microcrystalline cellulose (MCC) is a synthetic filler derived from wood pulp and used extensively as a tablet binder and capsule filler; it carries emerging concerns related to gut barrier function. Magnesium stearate, titanium dioxide, and silicon dioxide are other common flow agents that contribute nothing therapeutic. For someone managing a condition directly linked to intestinal inflammation, these additives are particularly ill-suited companions to a probiotic. Understanding how to read probiotic supplement labels for hidden fillers is an important step in making an informed choice.
Adequate CFU and Duration
Clinical trials demonstrating benefit in diverticular disease have used doses generally ranging from 1 billion to 24 billion CFU, with individual strain doses in specific studies at 5×108 to 109 CFU per strain. A multi-strain product delivering 15 billion CFU across 26 strains—as in MicroBiome Restore—provides therapeutically meaningful concentrations across multiple bacterial species. Duration also matters: trials demonstrating remission maintenance and prevention effects used supplementation periods of 6–12 months, suggesting that consistent long-term use is more relevant to diverticular disease outcomes than short-course supplementation.
Probiotic Selection Checklist for Diverticular Disease
Look for: Multi-strain formula with documented Lactobacillus and Bifidobacterium species; individually listed strains (not proprietary blends); 15+ billion CFU per serving; included prebiotic fibers; clean capsule material (pullulan preferred); no synthetic flow agents or fillers.
Avoid: Single-strain products; formulas containing microcrystalline cellulose, magnesium stearate, or titanium dioxide; products without third-party testing; very low CFU counts for multi-strain products (CFU diluted too thin across strains).
The Filler-Free Multi-Strain Formula Built for Gut Health
MicroBiome Restore contains all seven clinically relevant strains discussed in this article—L. reuteri, L. paracasei, L. acidophilus, B. lactis, L. salivarius, L. plantarum, L. rhamnosus—plus 19 additional evidence-backed strains, 7 certified organic prebiotic sources, and 80+ trace minerals. No MCC. No magnesium stearate. 15 billion CFU in a pullulan capsule.
Frequently Asked Questions
Can probiotics help with diverticulitis?
The evidence is increasingly promising, though still evolving. A 2025 systematic review and meta-analysis found that probiotic therapy was associated with significant improvement in abdominal pain (SMD 0.63, 95% CI: 0.38–0.88) and a substantial reduction in recurrence risk (RR 0.22) in patients with diverticular disease.[7] Two separate randomized controlled trials found that Lactobacillus reuteri ATCC PTA 4659 significantly reduced pain and inflammatory markers compared to placebo in acute uncomplicated diverticulitis—and shortened hospital stays.[3][4] Multi-strain formulations and longer treatment durations appear most beneficial. Probiotics are currently best understood as a complementary strategy alongside—not a replacement for—medical treatment during acute episodes.
What clears up diverticulitis?
Acute uncomplicated diverticulitis is typically managed with bowel rest, clear fluids, and—depending on severity—antibiotic therapy. Importantly, updated clinical guidelines in several countries have moved toward selective (rather than routine) antibiotic use in mild, uncomplicated cases, which is part of why probiotic adjunct therapy has gained research attention as a supportive tool during recovery. Dietary modification—particularly increasing fiber intake during remission—remains a cornerstone of long-term management. For long-term gut microbiome support, addressing underlying gut dysbiosis through targeted probiotic supplementation may help reduce the frequency of recurrent episodes.
Are probiotics safe to take during an acute diverticulitis flare?
The two RCTs of L. reuteri ATCC PTA 4659 specifically studied patients during an acute uncomplicated diverticulitis episode, with no safety concerns reported.[3][4] The three-strain combination trial (L. acidophilus, B. lactis, L. salivarius) similarly reported no adverse events during the acute phase.[5] That said, complicated diverticulitis—involving abscess, perforation, or fistula—requires immediate medical attention, and any supplementation decisions during a serious acute episode should involve your healthcare provider. Probiotics are not a substitute for emergency medical care in complicated presentations.
Which probiotic strains are best for diverticular disease?
Based on the current clinical evidence, the strongest strains for diverticular disease are Lactobacillus reuteri (two RCTs in acute uncomplicated diverticulitis), Lactobacillus paracasei/casei (prevention and SUDD remission maintenance in multiple trials), and the combination of Lactobacillus acidophilus, Bifidobacterium lactis, and Lactobacillus salivarius (reduced inflammatory markers in acute diverticulitis when combined with antibiotics). All are present in MicroBiome Restore alongside additional strains with broader gut health and anti-inflammatory properties. For additional context on specific strains, see our guide to clinically studied probiotic strains.
Can taking probiotics cause a diverticulitis flare?
There is no clinical evidence that probiotics trigger or worsen diverticulitis. To the contrary, existing RCTs specifically administered probiotics during acute diverticulitis episodes and found improved—not worsened—outcomes. Some individuals new to probiotic supplementation may experience mild, transient digestive changes during the first few days of use as the gut microbiome adjusts; this typically resolves quickly and is not indicative of a flare. If you have a history of complicated diverticulitis or are immunocompromised, consult your physician before starting any probiotic supplement.
Should I take a probiotic after antibiotics for diverticulitis?
This is one of the most well-supported applications for probiotic supplementation. Antibiotics—which are a standard treatment for moderate to severe diverticulitis—disrupt gut microbial balance broadly, which can paradoxically worsen the dysbiosis associated with diverticular disease over time. Taking probiotics after antibiotics to restore microbial diversity is supported by a broad evidence base. Spacing probiotic intake at least 2 hours from antibiotic doses helps ensure bacterial viability.
Supporting the Colon With a Science-First Approach
The emerging picture from the clinical literature is that diverticulitis is not simply a mechanical or dietary problem—it is, at its root, a microbiome problem. The consistent finding of dysbiosis in patients with diverticular disease, combined with randomized controlled trial evidence that specific probiotic strains can reduce pain, suppress inflammation, shorten hospital stays, and potentially prevent acute episodes, makes a compelling case for probiotic supplementation as a meaningful part of the diverticular disease management toolkit.
What matters most in translating this evidence to practice is choosing a formula that actually reflects the research: multi-strain diversity spanning the genera with documented benefit, sustained use rather than short courses, prebiotic support to fuel colonization, and a clean formulation free of the fillers and flow agents that work against gut health. Explore our complete guide to MicroBiome Restore to understand how each formulation decision was made—and why the absence of certain ingredients matters as much as what's included.
The colon's microbiome is a dynamic ecosystem, not a static condition. Consistent, targeted support with the right strains gives it the best possible chance of staying resilient.
Built Around the Evidence. Free of Everything Else.
MicroBiome Restore delivers 26 clinically studied probiotic strains, 7 certified organic prebiotics, and 80+ trace minerals in a filler-free pullulan capsule. Every ingredient earns its place by supporting your microbiome—never by making manufacturing easier or cheaper.
Medical Disclaimer
This article is for informational and educational purposes only. It does not constitute medical advice and is not a substitute for professional medical care, diagnosis, or treatment. Diverticulitis can be a serious medical condition; always consult your physician before making changes to your treatment plan, including the addition of probiotic supplements—especially during an acute episode or if you have been diagnosed with complicated diverticulitis.
References
- Strate, L. L., & Morris, A. M. (2019). Epidemiology, pathophysiology, and treatment of diverticulitis. Gastroenterology, 156(5), 1282–1298.e1. https://doi.org/10.1053/j.gastro.2018.12.033
- Piccioni, A., Franza, L., Brigida, M., Saviano, A., Zanza, C., Franceschi, F., & Ojetti, V. (2021). Gut microbiota and acute diverticulitis: Role of probiotics in management of this delicate pathophysiological balance. Journal of Personalized Medicine, 11(4), 298. https://doi.org/10.3390/jpm11040298
- Petruzziello, C., Migneco, A., Cardone, S., Covino, M., Saviano, A., Franceschi, F., & Ojetti, V. (2019). Supplementation with Lactobacillus reuteri ATCC PTA 4659 in patients affected by acute uncomplicated diverticulitis: a randomized double-blind placebo controlled trial. International Journal of Colorectal Disease, 34(6), 1087–1094. https://doi.org/10.1007/s00384-019-03295-1
- Ojetti, V., Saviano, A., Brigida, M., Petruzziello, C., Caronna, M., Gayani, G., & Franceschi, F. (2022). Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in reducing inflammatory markers in acute uncomplicated diverticulitis. European Journal of Gastroenterology & Hepatology, 34(5), 496–502. https://doi.org/10.1097/MEG.0000000000002342
- Petruzziello, C., Marannino, M., Migneco, A., Brigida, M., Saviano, A., Piccioni, A., Franceschi, F., & Ojetti, V. (2019). The efficacy of a mix of three probiotic strains in reducing abdominal pain and inflammatory biomarkers in acute uncomplicated diverticulitis. European Review for Medical and Pharmacological Sciences, 23(20), 9126–9133. https://doi.org/10.26355/eurrev_201910_19316
- Tursi, A., Danese, S., & Fiore, W. (2025). Lactobacillus paracasei CNCM I 1572 is better than placebo in preventing acute diverticulitis occurrence. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-025-10812-y
- Calini, G., Abd El Aziz, M. A., Paolini, L., Abdalla, S., Rottoli, M., Mari, G., & Larson, D. W. (2025). The impact of probiotics on clinical outcomes in diverticular disease: A systematic review and meta-analysis. Journal of Clinical Medicine, 15(1), 88. https://doi.org/10.3390/jcm15010088
- Soliman, M. G., Mansour, H. A., Hassan, W. A., & Shawky, E. (2023). Impact of oral probiotics in amelioration of immunological and inflammatory responses on experimentally induced acute diverticulitis. Probiotics and Antimicrobial Proteins, 15(5), 1113–1123. https://doi.org/10.1007/s12602-022-09969-7
- Tursi, A., Brandimarte, G., Giorgetti, G. M., & Elisei, W. (2006). Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: A prospective, randomized, open-label study. Journal of Clinical Gastroenterology, 40(4), 312–316. https://doi.org/10.1097/01.mcg.0000210092.77296.6d
- Lahner, E., Esposito, G., Zullo, A., Hassan, C., Cannaviello, C., Di Paolo, M. C., Pallotta, L., Garbagna, N., Grossi, E., & Annibale, B. (2012). High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World Journal of Gastroenterology, 18(41), 5918–5924. https://doi.org/10.3748/wjg.v18.i41.5918
- Lahner, E., Bellisario, C., Hassan, C., Zullo, A., Esposito, G., & Annibale, B. (2016). Probiotics in the treatment of diverticular disease: A systematic review. Journal of Gastrointestinal and Liver Diseases, 25(1), 79–86. https://doi.org/10.15403/jgld.2014.1121.251.srw
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!